Offered a flight to London as an alternative, Omisore's frustration intensified. Kenya Airways reported that she became aggressive with check-in staff, rejecting the new itinerary and demanding ...

Nancy Odindo, a journalist at TUKO.co.ke, brings over four years of experience covering politics, news, and feature stories across digital and print media in Kenya. The United States has halted its ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...

Sanofi is planning a $5.12bn share buyback programme in 2025. Image credit: Shutterstock / JHVEPhoto. Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of ...

After years in the wilderness, Kenya’s tiny rock and metal scene is exploding — and bands like Irony Destroyed, Last Year’s Tragedy and Rash are clawing their way up the charts. Very few ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi SAN-1.58%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...